The affinity-directed protein missile (AdPROM) system utilizes specific polypeptide binders
of intracellular proteins of interest (POIs) conjugated to an E3 ubiquitin ligase moiety to …

Targeted proteolysis of endogenous proteins is desirable as a research toolkit and in
therapeutics. CRISPR/Cas9-mediated gene knockouts are irreversible and often not feasible …

K-RAS is known as the most frequently mutated oncogene. However, the development of
conventional K-RAS inhibitors has been extremely challenging, with a mutation-specific …

The von Hippel–Lindau (VHL) protein serves to recruit the hypoxia-inducible factor alpha
(HIF1α) protein under normoxia to the CUL2 E3 ubiquitin ligase for its ubiquitylation and …

Small-molecule-induced protein depletion technologies, also called inducible degrons,
allow degradation of genetically engineered target proteins within cells and animals. Here …

The targeted degradation of membrane proteins would afford an attractive and general
strategy for treating various diseases that remain difficult with the current proteolysis …

Many diseases, especially cancers, result from aberrant or overexpression of pathogenic
proteins. Specific inhibitors against these proteins have shown remarkable therapeutic …

In recent years, the induction of target–protein degradation via the ubiquitin–proteasome
system (UPS) mediated by small molecules has attracted attention, and this approach has …

The induction of protein degradation by chimeric small molecules represented by proteolysis-
targeting chimeras (PROTACs) is an emerging approach for novel drug development. We …

Targeted protein degradation (TPD) has emerged as a promising therapeutic strategy. Most
TPD technologies use the ubiquitin–proteasome system, and are therefore limited to …